Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 eBioMedicine Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet Weight Loss Efficacy of Cagrilintide and Semaglutide gutsandgrowth Weight Loss Efficacy of Cagrilintide and Semaglutide gutsandgrowth CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current Amylin as a future obesity treatment introducing cagrilintideNote significant GI adverse effects cf. placebo but no apparent plateauing of weight loss after 26 weeks